NCT06762327View on ClinicalTrials.gov

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Solid Tumors
Interventions
DRUG

Ensartinib

ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT06762327 - Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer | Biotech Hunter | Biotech Hunter